Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN) announced Friday that their FDA-approved asthma therapy Tezspire reached ...

Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...

On Monday, Amgen Inc (AMGN) stock saw a decline, ending the day at $316.91 which represents a decrease of $-2.31 or -0.72% from the prior close of $319.22. The stock opened at $320.58 and touched a ...

Amgen reported a higher quarterly profit on Wednesday, driven by a 24% rise in sales of drugs for high cholesterol and ...

AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

Amgen ( AMGN 1.68%), a leader in biotechnology, released its third-quarter 2024 financial results on Oct. 30. The company ...

It’s been about one year since Amgen closed its $27.8 billion Horizon Therapeutics buyout and brought the rare disease drug ...

Thousand Oaks-based Amgen shared strong third-quarter results on Oct. 30, beating expectations, but all eyes appear to be on the big biotech's future, which includes trial data from its potentially ...

The Amgen STEM Learning Center — located at 260 Ramseyer Hall — opened Oct. 2, offering peer-led tutoring for first- and second-year students in introductory STEM courses. Susan Olesik, dean of ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Amgen (NASDAQ: AMGN) Q3 2024 Earnings Call Oct 30, 2024, 4:30 p.m. ET ...